Aerovate Therapeutics (NASDAQ: AVTE)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-14 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.450 | -0.490 | -0.0400 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Aerovate Therapeutics (NASDAQ: AVTE) through any online brokerage.
Other companies in Aerovate Therapeutics’s space includes: Immunovant (NASDAQ:IMVT), IDEAYA Biosciences (NASDAQ:IDYA), Kezar Life Sciences (NASDAQ:KZR), Inovio Pharmaceuticals (NASDAQ:INO) and Pharming (NASDAQ:PHAR).
The latest price target for Aerovate Therapeutics (NASDAQ: AVTE) was reported by BTIG on Friday, February 11, 2022. The analyst firm set a price target for 24.00 expecting AVTE to fall to within 12 months (a possible -6.80% downside). 1 analyst firms have reported ratings in the last year.
The stock price for Aerovate Therapeutics (NASDAQ: AVTE) is $25.75 last updated Today at August 15, 2022, 5:48 PM UTC.
There are no upcoming dividends for Aerovate Therapeutics.
Aerovate Therapeutics’s Q3 earnings are confirmed for Monday, November 14, 2022.
There is no upcoming split for Aerovate Therapeutics.
Aerovate Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.